OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on innovative ocular therapies, has announced a significant insider purchase. The company's Executive Chairman, Gabriele Cerrone, through Panetta Partners , has acquired 80,000 ordinary shares at $1.15 per share on NASDAQ. This acquisition has increased Cerrone's total shareholding to 9,801,570 shares, representing 28.97% of the company's issued share capital.
OKYO Pharma specializes in developing treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition currently lacking FDA-approved therapies. This insider purchase may signal confidence in the company's future prospects and ongoing clinical developments.
OKYO Pharma (NASDAQ: OKYO), una azienda biofarmaceutica in fase clinica specializzata in terapie oculari innovative, ha annunciato un'importante acquisizione da parte di un insider. Il Presidente Esecutivo dell'azienda, Gabriele Cerrone, attraverso Panetta Partners, ha acquistato 80.000 azioni ordinarie a $1,15 per azione su NASDAQ. Questa acquisizione ha aumentato la partecipazione totale di Cerrone a 9.801.570 azioni, che rappresentano il 28,97% del capitale sociale emesso dall'azienda.
OKYO Pharma è specializzata nello sviluppo di trattamenti per la malattia infiammatoria dell'occhio secco (DED), un mercato da miliardi di dollari, e il dolore corneale neuropatico (NCP), una condizione oculare attualmente priva di terapie approvate dalla FDA. Questa acquisizione interna potrebbe segnalare fiducia nelle prospettive future dell'azienda e nello sviluppo clinico in corso.
OKYO Pharma (NASDAQ: OKYO), una empresa biofarmacéutica en etapa clínica enfocada en terapias oculares innovadoras, ha anunciado una significativa compra por parte de un insider. El Presidente Ejecutivo de la empresa, Gabriele Cerrone, a través de Panetta Partners, ha adquirido 80.000 acciones ordinarias a $1.15 por acción en NASDAQ. Esta adquisición ha aumentado la participación total de Cerrone a 9.801.570 acciones, lo que representa el 28.97% del capital social emitido por la empresa.
OKYO Pharma se especializa en desarrollar tratamientos para la enfermedad inflamatoria del ojo seco (DED), un mercado multimillonario, y el dolor corneal neuropático (NCP), una condición ocular que actualmente carece de terapias aprobadas por la FDA. Esta compra interna podría señalar confianza en las perspectivas futuras de la empresa y en los desarrollos clínicos en curso.
OKYO 제약 (NASDAQ: OKYO)은 혁신적인 안과 치료에 집중하는 임상 단계의 생명공학 회사로, 중요한 내부자 구매를 발표했습니다. 회사의 회장 가브리엘레 체론은 파네타 파트너스를 통해 NASDAQ에서 80,000 주식을 주당 $1.15에 인수했습니다. 이 인수로 체론의 총 주식 보유량은 9,801,570 주식으로 증가했으며, 이는 회사가 발행한 주식 자본의 28.97%를 차지합니다.
OKYO 제약은 염증성 건성안 질환 (DED), 수십억 달러 규모의 시장과 신경병적 각막 통증 (NCP)에 대한 치료법 개발을 전문으로 하며, 현재 FDA 승인 치료법이 없는 안과 질환입니다. 이러한 내부자 구매는 회사의 미래 전망과 진행 중인 임상 개발에 대한 신뢰를 나타낼 수 있습니다.
OKYO Pharma (NASDAQ: OKYO), une entreprise bio-pharmaceutique en phase clinique spécialisée dans les thérapies oculaires innovantes, a annoncé un achat important par un insider. Le Président Exécutif de l'entreprise, Gabriele Cerrone, a acquis via Panetta Partners 80.000 actions ordinaires à 1,15 $ par action sur NASDAQ. Cette acquisition a porté la participation totale de Cerrone à 9.801.570 actions, représentant 28,97% du capital social émis de l'entreprise.
OKYO Pharma se spécialise dans le développement de traitements pour la maladie inflammatoire de l'œil sec (DED), un marché de plusieurs milliards de dollars, et la douleur cornéenne neuropathique (NCP), une condition oculaire actuellement dépourvue de thérapies approuvées par la FDA. Cet achat interne pourrait signaler une confiance dans les perspectives futures de l'entreprise et dans les développements cliniques en cours.
OKYO Pharma (NASDAQ: OKYO), ein biopharmazeutisches Unternehmen in klinischen Phasen, das sich auf innovativen Augentherapien konzentriert, hat einen bedeutenden Insider-Kauf bekannt gegeben. Der Executive Chairman des Unternehmens, Gabriele Cerrone, hat über Panetta Partners 80.000 Stammaktien zu $1,15 pro Aktie an der NASDAQ erworben. Durch diesen Erwerb hat sich Cerrones Gesamtbeteiligung auf 9.801.570 Aktien erhöht, was 28,97% des ausgegebenen Grundkapitals des Unternehmens entspricht.
OKYO Pharma ist auf die Entwicklung von Behandlungen für entzündliche Erkrankungen des trockenen Auges (DED), einem Milliardenmarkt, und neuropathische Hornhautschmerzen (NCP), einem augenmedizinischen Zustand, der derzeit keine von der FDA zugelassenen Therapien hat, spezialisiert. Dieser Insider-Kauf könnte Vertrauen in die zukünftigen Perspektiven des Unternehmens und die laufenden klinischen Entwicklungen signalisieren.
- Executive Chairman increased his stake in the company, potentially signaling confidence in OKYO's future
- Insider now owns 28.97% of the company's issued share capital, aligning management interests with shareholders
- Company is targeting multi-billion-dollar market opportunities in dry eye disease and neuropathic corneal pain
- None.
LONDON and NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 80,000 of the Company’s ordinary shares on NASDAQ at a price of US
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
How many shares did OKYO Pharma's Chairman acquire in the recent purchase?
What is the current shareholding percentage of OKYO Pharma's Chairman after the recent purchase?
What was the price per share for the recent insider purchase of OKYO stock?
What are the main therapeutic areas OKYO Pharma (OKYO) is focusing on?
